3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Pseudomyxoma Peritonei
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, B-Cell
1
Endometrial Neoplasms
1
Appendiceal Neoplasms
1
Interventions
Paclitaxel
7
Pemetrexed
3
Cisplatin
3
Carboplatin
3
pembrolizumab
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Radiotherapy
2
Nivolumab
2
FANG vaccine
2
Docetaxel
2
CP protocol
2
Brachytherapy
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
niraparib
1
larotrectinib
1
ipatasertib
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Neoplasms
×
Lansoprazole
×
Clear all
NCT03192059
2021-09-08
PRIMMO
University Hospital, Ghent
Phase 2
Completed
43 enrolled